Related Experiment Video

Updated: May 21, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Vandetanib for the treatment of metastatic medullary thyroid cancer

Nils Degrauwe1, Julie Ann Sosa, Sanziana Roman

  • 1University of Lausanne, Lausanne, Switzerland.

Clinical Medicine Insights. Oncology
|June 23, 2012
PubMed

Insights

Medullary thyroid cancer (MTC) is aggressive. Vandetanib is a new targeted therapy approved for advanced MTC, offering hope for patients with poor prognoses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Medullary thyroid cancer (MTC) is an aggressive malignancy.
  • MTC can be sporadic or linked to genetic syndromes involving RET protooncogene mutations.
  • Unresectable or metastatic MTC has a poor long-term prognosis.

Purpose of the Study:

  • To review the clinical studies supporting Vandetanib's approval for MTC.
  • To discuss the financial costs and side effects associated with Vandetanib therapy.
  • To examine Vandetanib's efficacy in other solid tumors.

Main Methods:

  • Review of pivotal clinical trials for Vandetanib in MTC.
  • Analysis of safety and efficacy data from these trials.
  • Exploration of Vandetanib's mechanism of action as a RET tyrosine kinase inhibitor.

Main Results:

  • Vandetanib demonstrated efficacy in patients with progressive, locally advanced, or metastatic MTC.
  • The drug's approval was based on studies showing significant clinical benefit.
  • Potential side effects and financial considerations were highlighted.

Conclusions:

  • Vandetanib represents a significant advancement in MTC treatment.
  • Targeted therapy inhibiting RET offers a new therapeutic option for advanced MTC.
  • Further research may explore Vandetanib's role in other cancers.
Keywords:
RETVandetanibmedullary thyroid cancer

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.